GlaxoSmithKline (GSK) which currently has 170 R&D staff in China has plans to boost up its staff to 350 by the end of 2009. According to Carol Zhu, head of operation management and alliances in GSK’s China R&D unit, the staff levels would remain static for three or four years after the increase, while the company will expand its facilities to accommodate further increases thereafter.
As part of its strategic plan to step up investment in biotech medicines, GSK has focused on China for furthering its R&D activities.